Yau JW, Rogers SL, Kawasaki R et al (2012) Meta-Analysis for eye disease (META-EYE) study group. global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564
Article PubMed PubMed Central Google Scholar
Agarwal D, Gelman R, Prospero Ponce C et al (2015) The vitreomacular interface in diabetic retinopathy. J Ophthalmol 2015:392–983
Mehta H, Gabrielle PH, Hashimoto Y et al (2024) One-Year anti-VEGF therapy outcomes in diabetic macular edema based on Treatment intensity: data from the fight retinal blindness! Regist Ophthalmol Retina S2468–6530(24):00182–00189. https://doi.org/10.1016/j.oret.2024.04.008
Inaltekin A, Bozkurt E, Kıvrak Y (2021) Factors associated with pain level in patients receiving intravitreal injection. J Curr Ophthalmol 33(3):323–329
Article PubMed PubMed Central Google Scholar
Levison AL, Kaiser PK (2014) Vitreomacular interface diseases: diagnosis and management. Taiwan J Ophthalmol 4:63–68
Xie P, Zheng X, Yu Y et al (2017) Vitreomacular adhesion or vitreomacular traction may affect antivascular endothelium growth factor treatment for neovascular age-related macular degeneration. Br J Ophthalmol 101(8):1003–1010
Akbar KhI, Mohamed MD, Mann SS et al (2015) Prevalence of vitreomacular interface abnormalities on spectral domain optical coherence tomography of patients undergoing macular photocoagulation for centre involving diabetic macular oedema. Br J Ophthalmol 99(8):1078–1081
Zapata MA, Figueroa MS, Esteban González E et al (2017) SERV-VMT study group. Prevalence of vitreoretinal interface abnormalities on spectral-domain OCT in healthy participants over 45 years of age. Ophthalmol Retina 1(3):249–254
Wells JA, Glassman AR, Ayala AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193–1203
Article PubMed CAS Google Scholar
Lin A, Xia H, Zhang A et al (2022) Vitreomacular interface disorders in proliferative diabetic retinopathy: an optical coherence TOMOGRAPHY STUDY. J Clin Med 11(12):32–66
Duman R, Çetinkaya E, Duman R (2018) Vitreomaküler Ara Yüzey Hastalıklarında Klinik. Tanı ve Sınıflandırma Current Retian 2(3):231–235
Yayla U, Sevik MO, Karabaş VL et al (2023) Real-world outcomes of intravitreal anti-vascular endothelial growth factor treatment for Diabetic macular edema in Türkiye: MARMASIA study group report No. 1. Turk J Ophthalmol 53:356–368
Article PubMed PubMed Central Google Scholar
Chang CK, Cheng CK, Peng CH (2017) The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF. Eye (Lond) 31(5):762–770
Article PubMed CAS Google Scholar
Liew G, Nguyen H, Ho IV et al (2021) Prevalence of vitreoretinal interface disorders in an Australian population: the blue mountains eye study. Ophthalmol Sci 1(2):100019
Article PubMed PubMed Central Google Scholar
Quinn NB, Steel DH, Chakravarthy U et al (2020) Assessment of the vitreomacular interface using high-resolution OCT in a population-based cohort study of older adults. Ophthalmol Retina 4(8):801–813
Lin A, Xia H, Zhang A et al (2022) Vitreomacular interface disorders in proliferative diabetic retinopathy: an optical coherence tomography study. J Clin Med 11(12):3266
Article PubMed PubMed Central Google Scholar
Delyfer MN, Legout P, Le Goff M et al (2020) Prevalence of epiretinal membranes in the ageing population using retinal colour images and SD-OCT: the alienor study. Acta Ophthalmol 98:830–838
Jarrar ZA, Ansari AS, Williams KM et al (2023) Prevalence, concordance, and heritability of vitreomacular interface abnormalities in a twin study. Invest Ophthalmol Vis Sci 64(10):9
Article PubMed PubMed Central Google Scholar
Yoon D, Rusu I, Barbazetto I (2014) Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities. Int Ophthalmol 34(4):817–823
Romano MR, Allegrini D, Guardia CD et al (2019) Vitreous and intraretinal macular changes in diabetic macular edema with and without tractional components. Graefe’s Arch Clin Exp Ophthalmol 257(1):1–8
Namba R, Kaneko H, Suzumura A et al (2019) In vitro epiretinal membrane model and antibody permeability: relationship with anti-VEGF resistance in diabetic macular edema. Investig Ophthalmol Vis Sci 60(8):2942–2949
Gandorfer A, Messmer EM, Ulbig MW et al (2000) Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 20(2):126–133
Article PubMed CAS Google Scholar
Kulikov AN, Sosnovskii SV, Berezin RD et al (2017) Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study. Clin Ophthalmol 11:1995–2002
Article PubMed PubMed Central Google Scholar
Mylonas G, Najeeb BH, Goldbach F et al (2022) The impact of the vitreomacular interface on functional and anatomical outcomes in diabetic macular edema treated with three different anti-VEGF agents: post hoc analysis of the protocol T study. Retina 42(11):2066–2074
Article PubMed CAS Google Scholar
Gong Y, Wang M, Li Q et al (2023) Evaluating the effect of vitreomacular interface abnormalities on anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema by optical coherence tomography: a systematic review and meta-analysis. Photodiagnosis Photodyn Ther 42:103555
Article PubMed CAS Google Scholar
Mikhail M, Stewart S, Seow F et al (2018) Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy. Graefe’s Arch Clin Exp Ophthalmol 256(8):1411–1418
Comments (0)